Myasthenia Gravis Market Growth, Trends, and Forecast by 2031

Coverage: By Treatment (Drug treatment, Rapid immunotherapies), and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2023 | Base Year: 2024 | Forecast Period: 2025-2031
  • Status : Data Released
  • Report Code : TIPRE00005412
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : January 27, 2025
Myasthenia Gravis Market Growth, Trends, and Forecast by 2031
Report Date: January 27, 2025   |   Report Code: TIPRE00005412 Email: sales@theinsightpartners.com

2024 Market Size

US$ 3.25 Bn

Base year value

2031 Forecast

US$ 5.43 Bn

Projected by 2031

CAGR 2025-2031

7.6 %

Growth rate

Addressable Market

US$ 30.82 Bn

(2025-2031)

The Myasthenia Gravis Market size is expected to reach US$ 5.43 Billion by 2031. The market is anticipated to register a CAGR of 7.6% during 2025-2031.

The Myasthenia Gravis Market report covers analysis By Treatment (Drug treatment, Rapid immunotherapies), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.

Purpose of the Report

The report Myasthenia Gravis Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Myasthenia Gravis Market Segmentation Treatment

  1. Drug treatment
  2. Rapid immunotherapies

Market Assessment and Insights

  • Global market for Myasthenia Gravis was valued at US$ 3.25 Billion in 2024
  • Annual market size is expected to reach US$ 5.43 Billion by 2031
  • Total addressable market (TAM) during 2025-2031 is projected to reach approximately US$ 30.82 Billion
  • Market is anticipated to register a CAGR of 7.6% during the forecast period
  • The United States represents a key market, supported by Increasing Prevalence of Myasthenia Gravis (MG), Advancements in Treatment Options, Rising Demand for Personalized Medicine, as well as evolving industry dynamics
  • Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
  • Market opportunities such as Emerging Markets, Advancements in Gene Therapy, Increase in Patient Support Services and Community Involvement are expected to influence market dynamics and addressable market
  • Report profiles industry participants, including Novartis AG, NIHON PHARMACEUTICAL CO., LTD, Grifols, S. A., Bausch Health, Alexion, F. Hoffmann-La Roche Ltd, Curavac, Bristol-Myers Squibb Company, Ra Pharmaceuticals, Inc, argenx, while analyzing competitive strategies and innovation developments
  • Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • Segmentations
  • Geography
  • Competitive Analysis
  • Language Preferences

Myasthenia Gravis Market: Strategic Insights

myasthenia-gravis-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Myasthenia Gravis Market Growth Drivers

  1. Increasing Prevalence of Myasthenia Gravis (MG):
    The rising incidence of Myasthenia Gravis, an autoimmune neuromuscular disorder, is a significant driver of the market. As awareness and diagnosis improve, more cases of MG are being identified, leading to a growing patient population in need of treatment and care options.
  2. Advancements in Treatment Options:
    Recent developments in the understanding of Myasthenia Gravis have led to more targeted and effective therapies. The introduction of newer biologics and monoclonal antibodies, along with advancements in immunosuppressive therapies, is expanding the treatment landscape and improving patient outcomes.
  3. Rising Demand for Personalized Medicine:
    The trend toward personalized or precision medicine is gaining traction in the MG market. This approach tailors treatments based on individual patient profiles, improving efficacy and minimizing side effects.

Myasthenia Gravis Market Future Trends

  1. Increased Use of Thymectomy:
    Thymectomy, the surgical removal of the thymus gland, is increasingly being used as a treatment option for patients with generalized Myasthenia Gravis, particularly in those with thymoma. Studies continue to highlight the long-term benefits of thymectomy, contributing to its growing use in combination with other treatments.
  2. Shift Toward Combination Therapies:
    There is a growing trend towards the use of combination therapies in the treatment of Myasthenia Gravis. Combining immunosuppressive drugs, biologics, and other treatments allows for a more comprehensive approach to managing the disease, offering better disease control and improved patient outcomes.
  3. Growing Focus on Improving Diagnosis and Early Detection:
    The development of more advanced diagnostic techniques, such as antibody testing and electrophysiological assessments, is allowing for earlier and more accurate diagnosis of Myasthenia Gravis.

Myasthenia Gravis Market Opportunities

  1. Emerging Markets:
    As the health care infrastructure improves in emerging markets, the opportunities for Myasthenia Gravis treatments are enormous. There is an untapped market with a growing patient base in these regions, such as parts of Asia-Pacific and Latin America, for effective MG therapies.
  2. Advancements in Gene Therapy:
    The development of gene therapy can prove promising in the treatment of Myasthenia Gravis. Gene therapies would directly target the genetic and molecular causes of the disease and could provide long-term, even curative solutions, for MG. Thus, further research and clinical trials in gene therapy create huge opportunities for innovation in the market.
  3. Increase in Patient Support Services and Community Involvement:
    An increased MG patient population allows expansion opportunities in the area of counseling, physical therapy, and other support groups. Further opportunity to expand the market includes community engagement and specialized services for enhancing the quality of life of MG patients.

Myasthenia Gravis Market Report Scope

Report Attribute Details
Market size in 2024 US$ 3.25 Billion
Market Size by 2031 US$ 5.43 Billion
Global CAGR (2025 - 2031) 7.6%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Treatment
  • Drug treatment
  • Rapid immunotherapies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Novartis AG
  • NIHON PHARMACEUTICAL CO., LTD
  • Grifols, S. A.
  • Bausch Health
  • Alexion
  • F. Hoffmann-La Roche Ltd
  • Curavac
  • Bristol-Myers Squibb Company
  • Ra Pharmaceuticals, Inc
  • argenx

Myasthenia Gravis Market Players Density: Understanding Its Impact on Business Dynamics

The Myasthenia Gravis Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

myasthenia-gravis-market-cagr

Key Selling Points

  1. Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Myasthenia Gravis Market, providing a holistic landscape.
  2. Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  3. Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  4. Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Myasthenia Gravis Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.

The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

Key companies of this market are: Novartis AG, NIHON PHARMACEUTICAL CO., LTD, Grifols, S.A., Bausch Health, Alexion, F. Hoffmann-La Roche Ltd, Curavac, Bristol-Myers Squibb Company, Ra Pharmaceuticals, Inc, argenx,

Key future trends in this market are -

The Myasthenia Gravis Market is estimated to witness a CAGR of 7.6% from 2025 to 2031.

The major factors driving the market are: Advancements in biologics and immunotherapies, Growing awareness and diagnostic rates, Rising prevalence of autoimmune disorders
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA